Joy Mangel

1.3k total citations
47 papers, 957 citations indexed

About

Joy Mangel is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Joy Mangel has authored 47 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 18 papers in Oncology and 14 papers in Genetics. Recurrent topics in Joy Mangel's work include Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Viral-associated cancers and disorders (6 papers). Joy Mangel is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Viral-associated cancers and disorders (6 papers). Joy Mangel collaborates with scholars based in Canada, United Kingdom and United States. Joy Mangel's co-authors include Michael Crump, Neil L. Berinstein, Kevin Imrie, Rena Buckstein, Nancy Pennell, David Spaner, David R. Anderson, Donald M. Arnold, Nancy M. Heddle and Mark Crowther and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Joy Mangel

46 papers receiving 938 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joy Mangel Canada	14	456	319	302	247	174	47	957
Shayna Sarosiek United States	16	182 0.4×	363 1.1×	183 0.6×	247 1.0×	119 0.7×	109	1.1k
James N. Butera United States	20	545 1.2×	165 0.5×	638 2.1×	172 0.7×	98 0.6×	55	1.2k
Cynthia Rutherford United States	18	201 0.4×	210 0.7×	264 0.9×	326 1.3×	208 1.2×	35	1.1k
W. Kincaid United Kingdom	5	184 0.4×	224 0.7×	37 0.1×	485 2.0×	178 1.0×	14	1.2k
Michel Pavic France	14	88 0.2×	105 0.3×	229 0.8×	121 0.5×	177 1.0×	96	901
Jonathan P. Kerr United Kingdom	8	133 0.3×	173 0.5×	205 0.7×	256 1.0×	212 1.2×	11	818
Wim Terpstra Netherlands	18	61 0.1×	183 0.6×	276 0.9×	542 2.2×	161 0.9×	36	1.0k
Andrei Braester Israel	13	96 0.2×	190 0.6×	129 0.4×	84 0.3×	163 0.9×	63	625
Wolfgang Lamm Austria	20	176 0.4×	115 0.4×	494 1.6×	151 0.6×	59 0.3×	76	1.0k
Okke de Weerdt Netherlands	17	85 0.2×	173 0.5×	250 0.8×	627 2.5×	77 0.4×	49	1.1k

Countries citing papers authored by Joy Mangel

Since Specialization

Citations

This map shows the geographic impact of Joy Mangel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Mangel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Mangel more than expected).

Fields of papers citing papers by Joy Mangel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Mangel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Mangel. The network helps show where Joy Mangel may publish in the future.

Co-authorship network of co-authors of Joy Mangel

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Mangel. A scholar is included among the top collaborators of Joy Mangel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Mangel. Joy Mangel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Knauer, Michael J., Alejandro Lazo‐Langner, Joy Mangel, et al.. (2024). Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 24(5). 305–315. 1 indexed citations

Rashedi, Iran, Kathryn Mangoff, Gail Klein, et al.. (2024). Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 66(1). 84–94. 1 indexed citations

Pandey, Arjun, Kathryn Mangoff, Gail Klein, et al.. (2024). Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial. SHILAP Revista de lepidopterología. 6(1). e1062–e1062. 2 indexed citations

Kanagalingam, Tharsan, et al.. (2023). Isolated Hodgkin lymphoma of the intracranial dura: A case report and review of the literature. SHILAP Revista de lepidopterología. 11(6). e7562–e7562. 2 indexed citations

Rashedi, Iran, Kathryn Mangoff, Douglas A. Stewart, et al.. (2023). PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL. European Journal Of Haematology. 111(2). 191–200. 7 indexed citations

Laidley, David, et al.. (2017). The Efficacy of PET-CT in Detecting Bone Marrow Involvement in Patients with Newly Diagnosed Lymphoma: A Retrospective Study. Blood. 130. 4160–4160. 1 indexed citations

Lazo‐Langner, Alejandro, et al.. (2016). Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review. CMAJ Open. 4(2). E236–E239. 2 indexed citations

Davison, Kelly, Vishal Kukreti, Stephen Couban, et al.. (2016). Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. Annals of Oncology. 28(3). 622–627. 15 indexed citations

Zeller, Michelle P., Sayra Cristancho, Joy Mangel, & Mark Goldszmidt. (2015). Back to Anatomy: Improving Landmarking Accuracy of Clinical Procedures Using a Novel Approach to Procedural Teaching. Southern Medical Journal. 108(6). 310–317. 2 indexed citations

10.

Olney, Harold J., et al.. (2014). Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine¹³¹-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma. Leukemia & lymphoma. 55(12). 2754–2760. 8 indexed citations

11.

Skeith, Leslie, Alejandro Lazo‐Langner, & Joy Mangel. (2013). Kidney and Pancreatic Extramedullary Relapse in Adult Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 2013. 1–5. 6 indexed citations

12.

Minuk, Leonard, Ian Chin‐Yee, Alejandro Lazo‐Langner, et al.. (2011). Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leukemia & lymphoma. 53(1). 57–63. 21 indexed citations

13.

Imrie, Kevin, et al.. (2011). High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. Leukemia & lymphoma. 52(10). 1882–1890. 13 indexed citations

14.

Zelcer, Shayna, et al.. (2010). Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation. Journal of Cancer Survivorship. 4(3). 218–224. 16 indexed citations

15.

Hicks, Lisa K., Rena Buckstein, Joy Mangel, et al.. (2008). Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplantation. 43(9). 701–708. 56 indexed citations

16.

Kovacs, M.J., Susan R. Kahn, Marc Rodger, et al.. (2007). A pilot study of central venous catheter survival in cancer patients using low‐molecular‐weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). Journal of Thrombosis and Haemostasis. 5(8). 1650–1653. 139 indexed citations

17.

Mangel, Joy, Heather A. Leitch, Joseph M. Connors, et al.. (2004). Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Annals of Oncology. 15(2). 283–290. 76 indexed citations

18.

Berinstein, Neil L. & Joy Mangel. (2004). Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma. Seminars in Oncology. 31(1 Suppl 2). 2–6. 10 indexed citations

19.

Mangel, Joy, Rena Buckstein, Kevin Imrie, et al.. (2002). Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Seminars in Oncology. 29(1). 56–69. 46 indexed citations

20.

Brox, Alan, et al.. (1998). ERYTHROCYTOSIS AFTER RENAL TRANSPLANTATION REPRESENTS AN ABNORMALITY OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS1. Transplantation. 66(8). 1053–1058. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact